# EXOMIND (BTL-995) for Reduction of Binge-eating

> **NCT06910592** · NA · COMPLETED · sponsor: **BTL Industries Ltd.** · enrollment: 23 (actual)

## Conditions studied

- Binge-Eating Disorder

## Interventions

- **DEVICE:** Treatment with BTL-995-rTMS

## Key facts

- **NCT ID:** NCT06910592
- **Lead sponsor:** BTL Industries Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-26
- **Primary completion:** 2023-12-15
- **Final completion:** 2024-03-11
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2025-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06910592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06910592, "EXOMIND (BTL-995) for Reduction of Binge-eating". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06910592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*